OGT Signs Licensing Deal for Colorectal Cancer Biomarkers

OXFORD, England--(BUSINESS WIRE)--Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital (OUS) and University of Oslo (UiO), for 12 highly promising colorectal cancer tissue biomarkers. The exclusive license allows OGT to commercialise any resulting test developed using these bioma

Feed Date: 
Wed, 2012-02-22 10:05